Articles tagged with Cancer Medication
A new study proposes a way to directly observe predicted ion-induced shock waves, which can help optimize ion-beam cancer therapy. Shock waves contribute to thermomechanical damage in tumour tissue, increasing the volume of cells exposed to reactive species.
Researchers found that breast cancer tumors impair learning and memory in mice before chemotherapy, suggesting cancer progression causes 'chemo brain' symptoms. After chemotherapy, cancer and drug therapy contribute to cognitive impairment.
Researchers discovered that fibroblast growth factors (FGFs) can regulate blood pressure and control disease associated with hypertension. FGF inhibitors could be used to target high blood pressure by altering sensitivity to angiotensin II.
Researchers developed a new technique to measure how cancer cells respond to drugs, using a device that can weigh cells with high accuracy. The method was tested on tumor cells from multiple-myeloma patients and showed promising results, correlating with clinical biomarkers used in treatment decisions.
A computer program called DrugPredict has been developed to repurpose FDA-approved drugs for new indications, including the potential treatment of epithelial ovarian cancer. The researchers found that common pain medications like aspirin can kill ovarian cancer cells, and NSAIDs may also have applications in this area.
Anita Mattson's research focuses on naturally occurring molecules known as dimeric chromanones, which have high biological activity and may become powerful dual-action treatments for drug-resistant cancers. Her goal is to develop a new class of catalysts using silanediols to control the synthesis of these compounds.
CANDLE, a scalable deep learning framework developed by Argonne's Exascale Deep Learning and Simulation Enabled Precision Medicine for Cancer project, was recognized with the award. The framework has achieved impressive results, including explaining over 92% of variance in drug response.
Researchers at Ludwig Institute for Cancer Research have identified a novel mechanism by which certain skin cancers, such as melanoma, resist cancer immunotherapy. The study found that an immune cell recruited to the tumor induces programmed suicide in killer T cells, and this interaction can be disrupted to improve treatment efficacy.
A UK study published in Scientific Reports has identified a novel cell signaling interaction that may prevent a key step in lung cancer progression. The research, conducted by the University of Kentucky, found that microRNA molecules can alter TGFβ activity and prevent epithelial-mesenchymal transition, a critical process in metastasis.
State cancer drug parity laws have had a mixed impact on treatment costs, with modest improvements for many patients and increased monthly out-of-pocket costs for others. The laws aim to ensure that oral cancer treatments are not more costly than infusions, but they may not fully address affordability concerns.
Researchers at Rice University and Northwestern University have developed a method to use nanoshells to deliver high doses of cancer-killing drugs inside tumors. The approach uses laser-activated gold nanoparticles to release approved drugs in laboratory cultures, demonstrating clinical applicability.
Cells can sense and mend damaged DNA caused by certain chemotherapy drugs. Researchers discovered a previously unknown repair complex that targets this type of damage. This finding could lead to more effective chemotherapy treatments by amplifying the killing power of existing drugs.
Researchers have developed a new platform for assessing anti-cancer drug efficacy in lung cancer, reducing attrition rates and increasing success of drugs. The 'explants' approach involves analyzing tumor tissue samples taken from patients immediately after surgery, providing patient-relevant data.
A comprehensive study from the Keck School of Medicine of USC found that IUD use is associated with a dramatic decrease in cervical cancer incidence. The analysis included data from 16 high-quality observational studies involving over 12,000 women worldwide.
Researchers discover that CDK8 plays a critical role in allowing cancer cells to use glucose for energy. Blocking CDK8 activity combined with glycolysis inhibitors slows cancer cell growth more effectively than either approach alone.
Researchers develop a new strategy for treating cancer by controlling chromatin packing densities, which determines gene expression and resistance to treatment. The approach has shown promising results in cellular cultures and is now being tested in animal models.
Current RECIST guidelines face challenges in measuring cancer response with emerging targeted therapies. Researchers propose a new baseline approach to track stability and separate tumor burden from treated areas.
A new study reveals that non-small cell lung cancers are driven by multiple genetic changes, including alterations in TP53 and other pathways. The findings suggest that combination therapies targeting these mutations may improve treatment outcomes and prevent drug resistance.
Researchers synthesized 30 flavanone derivatives to target NF-kappaB, identifying compounds with potent anti-inflammatory and cytotoxic activities against various cancer cell lines. The top-ranked compounds exhibited improved pharmacological profiles through conjugation of two pharmacophores.
Experts say pre-menopausal women with hormone-dependent advanced breast cancer should be included in clinical trials alongside older women. This could provide valuable insights into the best treatments for these patients, who make up a third of all advanced breast cancer cases globally.
Researchers have identified a connection between the PI3K pathway and telomere protection, revealing a potential target for cancer treatment. Inhibition of PI3K reduces TRF1 levels, leading to chromosome destabilization and cancer cell death.
Researchers developed a new three-step system targeting and eliminating colorectal cancer using nuclear medicine. The treatment achieved a 100-percent cure rate in mouse models without toxic effects.
Researchers at ITMO University have developed a novel approach to obtaining non-toxic magnetic photonic crystals, expanding their applications from photonics to biomedicine. These nanospheres can be used to design drugs for fighting thrombosis and cancer, and their biocompatibility makes them suitable for targeted drug delivery.
Researchers developed a way to control polymer molecule shape, leading to non-spherical nanoparticles that can encapsulate drugs. These natural-shaped plastic nanoparticles have shown preliminary evidence of entering tumor cells more easily than spherical ones.
Researchers mapped genetic alterations in normal mammary duct cells, identifying early changes that precede tumour development. This study provides new insights into breast cancer biology and may lead to more precision in screening and prevention.
The alisertib and TAK-228 combination shows promise in treating solid tumors, particularly triple-negative breast cancer. In a phase 1 clinical trial, the treatment was generally well-tolerated, with patients experiencing fatigue and decreased neutrophil count as common side effects.
Researchers investigate how gut bacteria metabolize chemotherapy drug irinotecan, finding that certain individuals are more likely to experience severe side effects. The study suggests analyzing patients' microbiomes before treatment could predict and prevent adverse reactions.
The Lancet Oncology Commission recommends prioritizing key areas for US$2 billion funding to advance cancer research and treatment, focusing on prevention, targeted interventions, and patient-centered data sharing. The report aims to improve cancer care for underserved groups and reduce health disparities.
A new open-source machine learning program at Georgia Tech predicts cancer drug effectiveness via genetic data, reducing human bias and increasing accuracy. The program aims to be widely used by researchers to improve treatment outcomes.
A new test targeting cancer drug effectiveness has been identified using protein HER3 levels, helping doctors tailor treatment for patients. The test shows that patients with high HER3 levels benefit from the drug, while those with low levels experience no effect, providing a more personalized approach to bowel cancer treatment.
A recent study by TGen-USC reveals that Precision Medicine in oncology is less precise for individuals with Latin American, African and Asian ancestry. A new genomic tool called LumosVar has been developed to help identify genetic variants, but more research is needed to overcome population differences.
Scientists have found that a rare genetic disease known as NGLY1 deficiency could hold the key to understanding resistance to cancer drugs. Dampening this enzyme may allow proteasome inhibitors to continue killing cancer cells, providing hope for new treatments.
A new class of antibody-drug conjugates, dubbed dual variable domain antibodies (DVD-ADCs), have been developed using a versatile double-decker technology. These pharmaceuticals selectively deliver drugs to cancer cells without harming healthy cells and tissues.
Scientists have successfully synthesized a promising anticancer molecule, BE-43547A(2), which shows unprecedented activity against pancreatic cancer stem cells. The compound reduces cancer stem cell proliferation by 21-fold and abolishes tumor-initiating capability.
Researchers have developed a new medicine, tarloxitinib, that brings high doses of anti-EGFR drugs to tumors while keeping toxic levels in healthy tissues. The prodrug-based approach has shown promising results in tests against lung cancer cells with EGFR exon 20 insertions.
A new analysis from the RAND Corporation estimates that biosimilar drugs could reduce healthcare spending in the US by $54 billion over the next decade. This is largely due to increased competition and regulatory changes, which will drive down prices and improve access to biologic drugs.
A survey of young white women found that over one in five have signs of indoor tanning addiction and three times more likely to meet criteria for dependence. Women with depression were most likely to weigh benefits against risks.
Researchers found that nerves stimulate the formation of new blood vessels that promote tumor growth in prostate cancer. They discovered an "angio-metabolic switch" triggered by norepinephrine binding to endothelial cells, which changes how cells metabolize glucose, favoring glycolysis.
A rare cancer in patients with breast implants, BIA-ALCL, may be on the rise and underreported. The cancer is linked to textured implants, which were introduced in the 1990s, and can lead to chronic inflammation and lymphoma, resulting in a good prognosis when treated promptly.
Researchers at the Francis Crick Institute have identified a novel protein that exclusively targets Wnt signalling in tumour cells, reducing growth of colon cancer cells without harming healthy cells.
Researchers found that high genetic diversity can prime new mutations causing drug resistance in yeast cells, with varying degrees of impact. The study highlights the importance of understanding genetic diversity's role in evolving drug resistance, with potential implications for treating antimicrobial and anticancer diseases.
The collaboration aims to establish a PDX Data Commons and Coordinating Center to integrate and share PDX treatment data for research. This will enhance precision in measuring drug-response and provide a clinical trial roadmap for piloting treatments.
Scientists at Wake Forest Baptist will use a $9.2 million grant to develop new molecularly targeted drugs and drug delivery systems for aggressive brain cancer glioblastoma. The goal is to directly attack tumor mass and cells in surrounding areas, increasing therapeutic efficacy.
A new AI model called druGAN enables the generation of novel molecules with desired properties, surpassing previous GAN-based approaches. The model uses reinforcement learning to generate effective molecular graphs, paving the way for improved pharmaceuticals.
A new study by American Cancer Society investigators finds workers at organizations with fewer than 25 employees are less likely to have been screened for three cancers. After adjusting for socioeconomic factors and insurance status, most of the difference in screening rates disappears.
Stanford researchers have found a new method to create bryostatin, a compound with potential for treating cancer, Alzheimer's disease, and HIV. The new synthetic supply will allow ongoing trials to continue testing its effectiveness.
The Van Andel Research Institute has been awarded two grants totaling $5.5 million to pursue clinical trials of epigenetic drugs combining with immunotherapies to enhance tumor response. The trials aim to test whether epigenetic therapies can reverse resistance to immunotherapy in lung and bladder cancers.
Researchers successfully deliver platinum-based chemotherapy drugs via nanoparticles to treat nonmuscle-invasive bladder cancer, reducing systemic absorption and toxicity. The study offers a potential less toxic clinical alternative to standard chemotherapy.
Researchers from Wellcome Trust Sanger Institute and Royal National Orthopaedic Hospital NHS Trust suggest a clinical trial of PI3K inhibitors for chordoma patients with specific genetic mutations. The study provides promising new treatment options for a rare and aggressive form of bone cancer.
Researchers at Dana-Farber Cancer Institute discovered a protein called Bclw that protects nerves from degeneration. Adding Bclw to nerve axons before exposure to chemotherapy drugs may prevent peripheral neuropathy symptoms.
The University of Houston and MD Anderson are launching a program to create a more diverse pool of medical doctors and scientists. The U-HAND Program aims to address racial and ethnic disparities in the healthcare workforce and health outcomes.
Researchers have developed a new class of drugs called PARP inhibitors to treat ovarian cancer by targeting synthetic lethality. These drugs aim to kill cancer cells by exploiting their genetic vulnerabilities, offering new hope to those with limited treatment options.
Researchers found that ceritinib, an FDA-approved drug for ALK-rearranged non-small cell lung cancer, also inhibits previously unknown targets. The study shows promise for repurposing the drug to target other cancers with networked alterations.
Researchers found that neratinib can block the function of Ras oncogenes through an unexpected process, killing non-small cell lung cancer cells resistant to afatinib. The study also discovered that neratinib triggers a seismic event in the plasma membrane, rapidly reducing expression of mutated K- and N-Ras genes.
Many opioid dosage combinations have no prescribing restrictions under Medicare formulary, suggesting an opportunity to limit opioid prescribing. Restricting coverage for prescription drugs is one strategy to decrease opioid prescribing.
A study published in Genome Research investigated the role of p53 in tumor suppression and found that no single gene serves as a backup 'second in command' to activate its functions. Instead, p53 relies on a multifunctional team of genes contributing to tumor suppression.
Researchers found that a protein named ZATT can eliminate DPCs with the help of another protein TDP2. Understanding how TDP2 and ZATT work together may improve cancer patient health outcomes. The discovery could lead to development of new drugs targeting these defenses.
A precision medicine trial is helping doctors target the genetic makeup of high-risk neuroblastoma tumors. Victoria Thompson, a two-year-old girl, is part of the trial and has seen promising results after innovative treatments.
New research explains why mTOR inhibitors can't fully eliminate cancer cells. The drugs target a cell regulator called mTOR, which controls mitochondrial structure and function, ultimately protecting cells from death.
Most new cancer drugs fail to extend or improve patient life, with many approved on surrogate measures. Only 51% of cancer indications showed survival or quality of life gains after a median 5 years on the market. This raises concerns about regulatory standards and the need for rigorous testing.